Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2V617F in granulocytes
Authors:
Open Access
- 10 August 2005
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 130 (5) , 797-799
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromesBlood, 2005
- JAK2 in Myeloproliferative Disorders Is Not Just Another KinaseCell Cycle, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasiaBlood, 2003